Navigation Links
JCI table of contents: Jan. 25, 2010
Date:1/25/2010

VACCINE DESIGN: Three is better than two when boosting vaccine effectiveness

To boost vaccine effectiveness molecules known as adjuvants are often included in the vaccine formulation. Adjuvants are most commonly used to increase the magnitude of vaccine-induced immune responses, specifically T cell immune responses. However, the quality of a T cell response can be more important than its quantity, and a team of researchers, at the National Institutes of Health, has now identified a way to increase the quality but not the quantity of a vaccine-induced T cell response in mice.

TLRs are a family of microorganism-sensing proteins that represent potential new vaccine adjuvants, as stimulating certain pairs of TLRs has a synergistic effect on the magnitude of immune responses in preclinical models. The team, led by Jay Berzofsky, found that when mice were immunized with an HIV peptide together with three molecules that bound different TLRs they mounted a more effective protective T cell response than did mice immunized with the HIV peptide together with any two of the ligands. Further analysis determined that the increased protection correlated with T cell responses of enhanced quality, rather than enhanced quantity. The authors therefore suggest that select TLR ligand combinations could be used to separately manipulate the quality and quantity of vaccine-induced T cell responses.

TITLE: Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

AUTHOR CONTACT:
Jay A. Berzofsky
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Phone: (301) 486-6874; Fax: (301) 480-0681; E-mail: berzofsk@helix.nih.gov.

View this article at: http://www.jci.org/articles/view/39293?key=76e6b3aa09052df83883


ONCOLOGY: Genetic variability in a tumor as an indicator of patient risk

Every cell within a tumor is not genetically identical and this genetic heterogeneity is thought to underlie tumor progression and resistance to therapeutics. A team of researchers, at the Dana-Farber Cancer Institute, Boston, and Memorial Sloan-Kettering Cancer Center, New York, has now developed methods to quantitatively describe intratumor genetic heterogeneity in primary human tumors.

The team, led by Kornelia Polyak and Franziska Michor, used these techniques to assess heterogeneity in several different types of human breast cancer. A high degree of genetic heterogeneity was detected both within and between distinct tumor cell populations. Further, in some tumors the degree of genetic heterogeneity was markedly different between the in situ and invasive cancer cell populations. As genetic diversity was associated with clinical variables, the authors suggest that it might provide a clinically useful biomarker for predicting prognosis and response to treatment. The idea that intratumor genetic heterogeneity might be a useful biomarker of a patient's risk of tumor progression and therapeutic resistance is further discussed by Lauren Merlo and Carlo Maley, at The Wistar Institute, Philadelphia, in an accompanying commentary.

TITLE: Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype

AUTHOR CONTACT:
Kornelia Polyak
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 632-2106; Fax: (617) 582-8490; E-mail: Kornelia_Polyak@dfci.harvard.edu.

Franziska Michor
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Phone: (646) 888-2802; Fax: (646) 422-0717; E-mail: michorf@mskcc.org.

View this article at: http://www.jci.org/articles/view/40724?key=d04af6bb12268301ccae

ACCOMPANYING COMMENTARY
TITLE: The role of genetic diversity in cancer

AUTHOR CONTACT:
Carlo C. Maley
The Wistar Institute, Philadelphia, Pennsylvania, USA.
Phone: (215) 495-6838; Fax: (215) 495-6829; E-mail: cmaley@alum.mit.edu.

View the PDF of this article at: http://www.jci.org/articles/view/42088?key=92ef686c26a5643a1911


VASCULAR BIOLOGY: The protein TGF-beta protects against blood vessel disease

Abdominal aortic aneurysm affects approximately 5% of elderly men and causes a substantial number of deaths. It is also associated with some genetic disorders such as Marfan syndrome. It is caused by degeneration of the wall of the main blood vessel leaving the heart (the aorta), which causes localized dilation; rupture of the aneurysm is what cuases death. Ziad Mallat and colleagues, at INSERM U970, France, have now identified a protective role for the molecule TGF-beta in a mouse model of abdominal aortic aneurysm in which disease is triggered by infusing the protein Ang II. Specifically, it was found that neutralizing TGF-beta activity worsened Ang IIinduced abdominal aortic aneurysm progression in mice. These data are in contrast to reports that TGF-beta promotes aortic aneurysm progression, and in an accompanying commentary, Harry Dietz, at Johns Hopkins University School of Medicine, Baltimore, discusses the complex roles of TGF-beta in different forms of aneurysm.

TITLE: TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin IIinfused mice

AUTHOR CONTACT:
Ziad Mallat
INSERM U970, Paris Cardiovascular Research Center, Paris, France.
Phone: 331-5398-8050; Fax: 331-5398-7952; E-mail: ziad.mallat@inserm.fr.

View this article at: http://www.jci.org/articles/view/38136?key=11418c50dbefe343cc12

ACCOMPANYING COMMENTARY
TITLE: TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions

AUTHOR CONTACT:
Harry C. Dietz
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Phone: (410) 614-0701; Fax: (410) 614-2256; E-mail: hdietz@jhmi.edu.

View the PDF of this article at: http://www.jci.org/articles/view/42014?key=92ef686c26a9363a1911


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. JCI table of contents: Sept. 4, 2007
4. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Implantable device designed to detect, stop seizures under study at MCG
10. Stevens Health, Technology and Society roundtable: Sept. 19
11. Fruity vegetables and fish reduce asthma and allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Rock Hill, SC (PRWEB) , ... March 22, 2017 , ... ... team, are expanding their patient base to accept new patients in need of skilled ... years of experience, India Hook Dental Care offers pediatric patients routine treatments, including cavities, ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Last year, ... to a US Department of Agriculture report. While excess dairy can be caused ... a role. Lactose sensitivity is the inability to properly digest lactose, a sugar found ...
(Date:3/22/2017)... VA (PRWEB) , ... March 22, 2017 , ... ... asset protection assistance and financial consultations to families and business owners in the ... support for the local American Cancer Society Relay For Life event. , Each ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... planning services to regional families and business owners, is joining the Teen Recovery ... people in the area. , A growing number of Oklahoma teens and adolescents ...
(Date:3/22/2017)... Kingston, NC (PRWEB) , ... March 22, 2017 , ... ... planning assistance to families and business professionals throughout the coastal plains region, is initiating ... struggling to overcome cancer. , Dillyn was first diagnosed with leukemia on a Friday ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 TFS is pleased to announce the ... Tumaian , two global executive positions in Medical Affairs and Clinical ... Leadership Team and will report to Dr. Montse Barceló , ... ... 10 years of medical and scientific expertise gained across leading biopharmaceutical ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
(Date:3/22/2017)... March 22, 2017 NetworkNewsWire Editorial Coverage  ... Deciphering ... differing statements by White House officials. Federal laws are at ... for medical and/or recreational use, and businesses like SinglePoint, Inc. ... (NASDAQ: CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, Inc. ...
Breaking Medicine Technology: